Research Progress of the Treatment of PD-1 Immune CheckpointInhibitors in Oral Squamous Cell Carcinoma

Authors

  • Yetao Wang Department of Hematology and Oncology, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang, 315000, China; Department of stomatology, Longsai Hospital, Ningbo, Zhejiang, 315200, China
  • Suying Qian Department of Hematology and Oncology, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang, 315000, China;Ningbo Institute of life and Health industry, University of Chinese Academy of Sciences, Ningbo, Zhejiang, 315200, China;Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang, 315200, China
  • Kesang Li Department of Hematology and Oncology, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang, 315000, China;Ningbo Institute of life and Health industry, University of Chinese Academy of Sciences, Ningbo, Zhejiang, 315200, China;Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang, 315200, China

DOI:

https://doi.org/10.30564/jor.v2i2.2429

Abstract

Targeted immune checkpoint-based immunotherapy has achieved remarkable success in the treatment of malignant tumors. Immune checkpoint inhibitor-programmed cell death protein 1 (PD-1) antibody opens a new era of immunotherapy for platinum-refractory recurrent/metastatic oral squamous cell carcinoma (OSCC). The overall survival of patients treated with immunological checkpoint inhibitors was significantly prolonged, and the overall incidence of grade 3-4 drug-related adverse events (AEs) occurred was lower; however, there are still some challenges to the PD-1’s application in OSCC clinic treatment. This article is just to briefly highlight the development of such application to date.

Keywords:

Anti-PD-1; Immune checkpoint inhibitors; Immunotherapy; Oral squamous cell carcinoma

References

[1] Sievilainen M, Almahmoudi R, Al-Samadi A, Salo T, Pirinen M, Almangush A. The prognostic value of immune checkpoints in oral squamous cell carcinoma. Oral diseases, 2018. DOI: 10.1111/odi.12991

[2] Chen Y, Li Q, Li X, et al. Blockade of PD-1 effectively inhibits in vivo malignant transformation of oral mucosa. Oncoimmunology, 2018, 7(2): e1388484. DOI: 10.1080/2162402X.2017.1388484. eCollection 2018

[3] Jiang C, Yuan F, Wang J, Wu L. Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages. Immunobiology, 2017, 222(4): 651-7. DOI: 10.1016/j.imbio.2016.12.002. Epub 2016 Dec 14

[4] Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral oncology, 2009, 45(4-5): 309-16. DOI: 10.1016/j.oraloncology.2008.06.002. Epub 2008 Sep 18

[5] Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008, 26:677-704.DOI: 10.1146/annurev.immunol.26.021607.090331

[6] Cho YA, Yoon HJ, Lee JI, Hong SP, Hong SD. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral oncology, 2011, 47(12): 1148-53. DOI: 10.1016/j.oraloncology.2011.08.007. Epub 2011 Sep 10

[7] Tsushima F, Tanaka K, Otsuki N, et al. Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral oncology, 2006, 42(3): 268-74. DOI: 10.1016/j.oraloncology.2005.07.013. Epub 2005 Nov 3

[8] Zheng P, Zhou Z. Human cancer immunotherapy with PD-1/PDL1blockade [J]. Biomark Cancer, 2015, 7(Suppl 2): 15-18. DOI: 10.4137/BIC.S29325

[9] Yearley JH, Gibson C, Yu N, et al. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clinical cancer research: an official journal of the American Association for Cancer Research, 2017, 23(12): 3158-67. DOI: 10.1158/1078-0432.CCR-16-1761

[10] Mandal R, Senbabaoglu Y, Desrichard A, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI insight, 2016, 1(17): e89829. DOI: 10.1172/jci.insight.89829

[11] Kansy BA, Concha-Benavente F, Srivastava RM, et al. PD-1 Status in CD8(+) T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. Cancer research, 2017, 77(22): 6353-64. DOI: 10.1158/0008-5472.CAN-16-3167. Epub 2017 Sep 13

[12] Mattox AK, Lee J, Westra WH, et al. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4(+) TILs in the Presence of PD-L1(+) TAMs. Cancer research, 2017, 77(22): 6365-74. DOI: 10.1158/0008-5472.CAN-16-3453. Epub 2017 Sep 25

[13] Zhang P, Ouyang S, Wang J, et al. Levels of programmed death-1 and programmed death ligand-1 in the peripheral blood of patients with oral squamous cell carcinoma and its clinical implications. West China journal of stomatology, 2015, 33(5): 529-33. URL:http://www.ncbi.nlm.nih.gov/pubmed/26688950

[14] Malaspina TS, Gasparoto TH, Costa MR, et al. Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. Cancer immunology, immunotherapy: CII 2011, 60(7): 965-74. DOI: 10.1007/s00262-011-1007-5. Epub 2011 Mar 27

[15] Weber M, Wehrhan F, Baran C, et al. PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma. Oncotarget, 2017, 8(68): 112584-97. DOI: 10.18632/oncotarget.22576. eCollection 2017 Dec 22

[16] Ferris RL, Blumenschein G, Jr., Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. The New England journal of medicine, 2016, 375(19): 1856-67.

[17] DOI: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17

[18] de Vicente JC, Rodriguez-Santamarta T, Rodrigo JP, Blanco-Lorenzo V, Allonca E, Garcia-Pedrero JM. PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2019, 28(3): 546-54. DOI: 10.1158/1055-9965.EPI-18-0779. Epub 2018 Nov 28

[19] Fusi A, Festino L, Botti G, et al. PD-L1 expression as a potential predictive biomarker. The Lancet Oncology, 2015, 16(13): 1285-7. DOI: 10.1016/S1470-2045(15)00307-1

[20] Polverini PJ, D’Silva NJ, Lei YL. Precision Therapy of Head and Neck Squamous Cell Carcinoma. Journal of dental research, 2018, 97(6): 614-21. DOI: 10.1177/0022034518769645. Epub 2018

[21] Apr 12

[22] Rexer H. [Study on therapy of metastasized or locally advanced urothelial cancer: A phase III randomized clinical trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel or vinflunine in subjects with recurrent or progressive metastatic urothelial cancer (Keynote 045) - AP 48/15 der AUO]. Der Urologe Ausg A, 2015; 54(9): 1287-90. DOI: 10.1007/s00120-015-3934-9

[23] Burtness B, Harrington KJ, Greil R et al. KEYNOTE-048: phase 3 study of first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). ESMO Meeting, 2018.

[24] Ferris RL, Blumenschein G, Jr., Fayette J, et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head andneck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral oncology, 2018, 81: 45-51. DOI: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17

[25] Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T, Konishi I. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol., 2016, 21: 462-473. DOI: 10.1007/s10147-016-0959-z

[26] Segal NH. Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. J Clin Oncol., ASCO meeting abstracts, 2015, 33(Suppl): abstr 3011.

[27] Chervin CS, Brockstein B. Current clinical immunotherapeutic approaches for head and neck cancer. F1000Res. Epub 2016 May 5. DOI: 10.12688/f1000research.7762.1

[28] Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (Lond), 2014, 515: 563-567. DOI: 10.1038%2Fnature14011

[29] Hang W, Xu ZX, Zhang Q, Lu X, Liu G. [Immune checkpoint inhibitor therapy in advanced head and neck cancer]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017;52(1):67-70. (In Chinese) DOI: 10.3760/cma. j. issn.1673-0860.2017.01.015

[30] Argiris A, Harrington KJ, Tahara M, et al. Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Front Oncol., 2017, 7: 72.

[31] DOI: 10.3389/fonc.2017.00072

[32] Saleh K, Eid R, Haddad FG, Khalife-Saleh N, Kourie HR. New developments in the management of head and neck cancer - impact of pembrolizumab. Therapeutics and clinical risk management, 2018, 14: 295-303. DOI: 10.2147/TCRM. S125059

[33] Wise-Draper TM, Old MO, Worden FP, et al. Phase II multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma. J Clin Oncol. 2018, 36(suppl): abstr 6017.

[34] Uppaluri R, Zolkind P, Lin T, et al. Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma. (HNSCC). J Clin Oncol., 2017, 15(suppl): 6012. DOI: 10.1200/JCO.2017.35.15_suppl.6012

[35] Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine, 2012, 366(26): 2443-54. DOI: 10.1056/NEJMoa1200690

[36] O’Donnell JS, Long GV, Scolyer RA, Teng MW, Smyth MJ. Resistance to PD1/PDL1 checkpoint inhibition. Cancer treatment reviews, 2017, 52: 71-81. DOI: 10.1016/j. ctrv.2016.11.007

[37] Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science translational medicine, 2016, 8(328): 328rv4. DOI: 10.1126/scitranslmed. aad7118

[38] Rafiq S, Yeku OO, Jackson HJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nature biotechnology, 2018, 36(9): 847-56. DOI: 10.1038/nbt.4195

[39] Economopoulou P, Perisanidis C, Giotakis EI, Psyrri A. The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications. Annals of translational medicine, 2016, 4(9): 173. DOI: 10.21037/atm.2016.03.34

[40] Pan D, Kobayashi A, Jiang P, et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science, 2018, 359(6377): 770-5. DOI: 10.1126/science. aao1710

[41] Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science, 2018, 359(6377): 801-6. DOI: 10.1126/science. aan5951

[42] Guerrero-Preston R, White JR, Godoy-Vitorino F et al. High-resolution microbiome profiling and genome wide arrays uncover bacteria driven alterations of oncogenic and immune pathways in head and neck cancer patients treated with surgery, chemo-radiation and PD-1 checkpoint blockade therapy. Cancer Resh, 2017, 77(Suppl 13): 1018-1018.

Downloads

How to Cite

Wang, Y., Qian, S., & Li, K. (2020). Research Progress of the Treatment of PD-1 Immune CheckpointInhibitors in Oral Squamous Cell Carcinoma. Journal of Oncology Research, 2(2), 9–15. https://doi.org/10.30564/jor.v2i2.2429

Issue

Vol. 2 , Iss. 2 (July 2020)

Article Type

Articles

License

Copyright and Licensing

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

Journal of Oncology Research publishes accepted manuscripts under Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). Authors who submit their papers for publication by Journal of Oncology Research agree to have the CC BY-NC 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for non-commercial use. As long as you follow the license terms and original source is properly cited, anyone may copy, redistribute the material in any medium or format, remix, transform, and build upon the material.

License Policy for Reuse of Third-Party Materials

If a manuscript submitted to the journal contains the materials which are held in copyright by a third-party, authors are responsible for obtaining permissions from the copyright holder to reuse or republish any previously published figures, illustrations, charts, tables, photographs, and text excerpts, etc. When submitting a manuscript, official written proof of permission must be provided and clearly stated in the cover letter.
The editorial office of the journal has the right to reject/retract articles that reuse third-party materials without permission.

Journal Policies on Data Sharing

We encourage authors to share articles published in our journal to other data platforms, but only if it is noted that it has been published in this journal.